A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 12 Weeks Treatment With 4 Doses of LIK066 Compared to Placebo in Japanese Patients With Obesity Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2018
At a glance
- Drugs LIK 066 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 13 Apr 2018 Planned End Date changed from 21 Sep 2018 to 23 Jul 2018.
- 13 Apr 2018 Planned primary completion date changed from 21 Sep 2018 to 23 Jul 2018.
- 14 Dec 2017 Status changed from not yet recruiting to recruiting.